Musculoskeletal System Disorders Market Research Report - Global Forecast till 2027

Global Musculoskeletal System Disorders Market Research Report: By Type (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Psoriatic Arthritis, Ankylosing Spondylitis, Others), By Treatment (Biologics, Corticosteroids, Physical Therapy, Protein Therapy, Composite Grafts, Others) and By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others) – Forecast to 2027

ID: MRFR/HC/6760-HCR | February 2021 | Region: Global | 111 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast


Global Musculoskeletal System Disorders Market is expected to cross USD 5.73 Billion by 2025 at a CAGR of 5.3%.


Market Synopsis


The number of musculoskeletal system disorder cases is increasing globally, fueling market growth. Musculoskeletal system disorders are the second-highest contributor to global disability and an estimated 20%–33% of people across the globe live with a painful musculoskeletal condition.


Musculoskeletal disorders are most common in low- and middle-income countries and these disorders require lifelong care to manage.


Market Influencer


Rising prevalence of musculoskeletal disorders and increasing reimbursement offered to patients by health insurance providers.


Market Drivers



  • Growing global geriatric population.



  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of musculoskeletal system disorders.



  • Increasing research and development of new drugs to treat musculoskeletal disorders. For instance, in 2017–2018, the National Institute of Health Research (NIHR) spent approximately USD 13.46 million (GBP 11.1 million) on research on musculoskeletal disorders.



  • Rising prevalence of work-related musculoskeletal disorders. For example, the prevalence in the fiscal year 2017–2018 was about 469,000 in the UK.



  • Rising awareness of advanced treatment for musculoskeletal disorders.



  • Launch of new medication to manage the symptoms of chronic musculoskeletal system disorders.


Market Restraints



  • High treatment costs.



  • Availability of alternative therapies such as traditional medicine and physiotherapy



  • Need for specialized equipment to diagnose and treat musculoskeletal system disorders.


Segmentation


By Type



  • Rheumatoid Arthritis: The largest segment of the market, rheumatoid arthritis afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.



  • Osteoarthritis: This disorder generally afflicts elderly people. As of 2018, about 9.6% of men and 18% of women over 60 had symptomatic osteoarthritis worldwide and over a quarter of those afflicted could not perform daily activities.



  • Osteoporosis: The fastest-growing segment, over 75 million people suffer from osteoporosis in Europe, the US, and Japan. This number is growing in developing countries and the disorder is responsible for millions of fractures worldwide. By 2050, osteoporosis is expected to be responsible for a 310% increase in hip fractures for men and a 240% increase for women, as compared to rates in 1990.



  • Psoriatic Arthritis: This autoimmune disorder afflicts roughly 3 out of every 10 individuals who have psoriasis. With over 100 million people afflicted globally with psoriasis, psoriatic arthritis afflicts almost 30 million individuals.



  • Ankylosing Spondylitis: The tendency to develop this condition is genetic, with males twice to three times more likely to be afflicted than women.



  • Fibromyalgia: A very common ailment, about 80%–90% of sufferers of fibromyalgia are women.



  • Others: This segment covers musculoskeletal disorders such as tendinitis and carpal tunnel syndrome.


By Treatment



  • Biologics: The fastest-growing segment, biologics find increasing application in the treatment of rheumatoid arthritis. A rise in the number of FDA approvals for biologics to treat musculoskeletal system disorders is a key factor for the growth of the segment.



  • Corticosteroids: The largest segment, corticosteroids are the preferred treatment for many musculoskeletal system disorders as they reduce inflammation and suppress immune system activity.



  • Physical Therapy: Used to manage almost all chronic musculoskeletal system disorders, physical therapy is prescribed in conjunction with medication.



  • Extracorporeal Shock Wave Therapy: Used to manage pain, this therapy excels in providing fast-acting relief without the use of painkillers. Used extensively in managing musculoskeletal system disorders.



  • Protein Therapy: A novel method used to combat several musculoskeletal system disorders; it involves the ingestion of protein via changes in diet and artificially produced proteins.



  • Synthetic Bone Graft: An expensive and complex treatment option, synthetic bone grafts have been used to replace bones made too brittle by osteoporosis and other musculoskeletal system disorders.



  • Composite Grafts: Used for several bone replacement and repair procedures.



  • Demineralized Bone Matrix: The treatment method is used in bone transplants where the biological activity of the graft is more important than its mechanical properties.



  • Others: This segment covers alternative treatment methods such as gene therapy and chiropractic care.


By End User



  • Hospitals and Clinics: The largest segment, hospitals and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with musculoskeletal system disorders. Growing awareness and increasing efficiency of musculoskeletal system disorder treatment are projected to drive the growth of this segment during the forecast period.



  • Ambulatory Surgical Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.



  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: The largest regional market, the prevalence of musculoskeletal system disorders is high in the Americas; the region also has a well-established healthcare industry.



  • Europe: An increasing geriatric population is leading to a rise in the number of musculoskeletal system disorder cases.



  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of people afflicted with musculoskeletal system disorders due to bad posture brought on by lifestyle changes, aging, and genetic predisposition.



  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.


Key Players



  • AB Science (France)

  • AbGenomics International, Inc. (US)

  • Alder BioPharmaceuticals,Inc. (US)

  • Amgen Inc. (US)

  • Lexicon Pharmaceuticals, Inc. (US)

  • LG Chem (South Korea)

  • OrthoTrophix, Inc. (US)

  • Tarsa Therapeutics, Inc. (US)

  • PhytoHealth Corporation (Taiwan)

  • Eisai Co., Ltd (Japan)

  • Astellas Pharma Inc. (Japan)

  • AstraZeneca (UK)

  • Baxter (US)

  • GlaxoSmithKline PLC (UK)



Frequently Asked Questions (FAQ) :


The musculoskeletal system disorders market is projected to grow at a 5.3% CAGR between 2019-2025.

The Americas are predicted to have the largest share in the musculoskeletal system disorders market.

The musculoskeletal system disorders market is predicted to touch USD 5.73 billion by 2025.

Key competitors in the musculoskeletal system disorders market include GlaxoSmithKline PLC (UK), Baxter (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Eisai Co., Ltd (Japan), PhytoHealth Corporation (Taiwan), Tarsa Therapeutics, Inc. (US), OrthoTrophix, Inc. (US), LG Chem (South Korea), Lexicon Pharmaceuticals, Inc. (US), Amgen Inc. (US), Alder BioPharmaceuticals,Inc. (US), AbGenomics International, Inc. (US), and AB Science (France).



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.